News

Published 2024-04-26

Disruptive Pharma raises 27 million SEK to conduct clinical study on its improved sorafenib product DPH001 and to nominate second product candidate

PRESS RELEASE / PRESSMEDDELANDE Disruptive Pharma offentliggör utfall i ...

News

Published 2024-04-05

PRESSMEDDELANDE – Idag inleds teckningstiden för Disruptive Pharmas företrädesemission

Idag inleds teckningstiden i Disruptive Pharma Holding AB (publ) (”Disru...

News

Published 2024-04-02

Pressmeddelande Disruptive Pharma offentliggör prospekt med anledning av förestående företrädesemission

INFORMATIONEN I DETTA PRESSMEDDELANDE ÄR INTE AVSEDD ATT PUBLICERAS, OFF...

News

Published 2024-04-02

Kommuniké från extra bolagsstämma i Disruptive Pharma Holding AB

Distruptive Pharma Holding AB (“Bolaget”) har idag, den 2 ap...

News

Published 2024-02-28

Disruptive Pharma Holding AB (publ) avser att genomföra en företrädesemission om cirka 35 MSEK

PDF Pressmeddelande: PM Launch Release Disruptive Pharma Holding AB Styr...

News

Published 2023-12-08

Welcome Sven Undeland – Commercial Director

We welcome Sven Undeland as the new Commercial Director at Disruptive Ph...

News

Published 2023-11-29

Welcome Sofia Mogensen – Director Project Management

We are happy to announce Sofia, our new Project Manager. With 20 years i...

News

Published 2023-08-23

Positive Preclinical Results Unveiled for DPH001

We’re delighted to share positive results from our recent preclini...

News

Published 2023-06-27

Disruptive Pharma announces DPH001 pipeline project

We are excited to announce that Disruptive Pharma is initiating the deve...

News

Published 2022-09-01

Welcome Malin Vågerö – Director R&D at Disruptive Pharma

As an excellent addition to team Disruptive Pharma we are now happy to a...

News

Published 2022-07-06

Disruptive Pharma raises 41 million SEK to develop pipeline project towards clinical stage

We have some exciting news to share just before the summer – Disruptive ...